Skip to main content
SpringerLink
Log in

Treatment of Multiple Sclerosis with ACTH and Corticosteroids

  • Chapter
Treatment of Multiple Sclerosis

Part of the book series: Clinical Medicine and the Nervous System ((CLIN.MED.NERV.))

Abstract

Adrenocorticotrophic hormone (ACTH) and glucocorticosteroids (GCS) have potent anti-inflammatory and immunosuppressive effects. They were introduced as therapeutic agents in the late 1940s and in spite of their limitations and adverse effects GCS remain the mainstay of treatment for allograft protection and for autoimmune diseases including multiple sclerosis (MS). In this chapter I will discuss the physiology and pharmacology of these agents as it relates to their use in MS. For more detailed discussion of the pharmacology of these hormones the interested reader is referred elsewhere (AHFS 1990; Haynes 1990). I will review the literature which provides the rationale for why, when, and how we use these agents in MS. I will also present my current recommendations for their use and suggest future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Abbruzzese G, Gandolfo C, Loeb C (1983) Bolus methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci 4: 169–172

    PubMed  CAS  Google Scholar 

  • AHFS (1990) Pituitary and adrenal hormones and synthetic substitutes: In: McEvoy GK (ed), AHFS Drug Information 90. American Society of Hospital Pharmacists, Bethesda, pp 1722–1745, 1820–1824

    Google Scholar 

  • Alexander L, Cass LJ (1963) The present status of ACTH therapy in multiple sclerosis. Ann Int Med 58: 454–71

    PubMed  CAS  Google Scholar 

  • Alexander L, Cass Li (1971) ACTH-induced adrenocortical response patterns in multiple sclerosis and their relation to the clinical effectiveness of ACTH therapy. Confinia Neurologica 33: 1–24

    PubMed  CAS  Google Scholar 

  • Alexander L, Berkeley AW, Alexander AM (1961) Multiple sclerosis prognosis and treatment. Charles C Thomas, Springfield, ILL

    Google Scholar 

  • Atkinson JP, Frank MM (1973) Effect of cortisone therapy on serum complement components. J Immunol 111: 1061–1066

    PubMed  CAS  Google Scholar 

  • Baker (1967) Intrathecal methylprednisolone for multiple sclerosis: evaluation by a standard neurological rating. Ann Aller 25: 665–672

    CAS  Google Scholar 

  • Balow JE, Rosenthal AS (1973) Glucocortical suppression of macrophage inhibition factor. J Exp Med 137: 1031–1039

    PubMed  CAS  Google Scholar 

  • Barnes MP, Bateman DE, Cleland PG et al. (1985) Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 48: 157–159

    PubMed  CAS  Google Scholar 

  • Baumhefner RW, Tourtellotte WW, Syndulko K, Staugaitis A, Shapshak P (1989) Multiple sclerosis intra-blood-brain-barrier IgG synthesis: effect of pulse intravenous and intrathecal corticosteroids. Ital J Neurol Sci 10: 19–32

    PubMed  CAS  Google Scholar 

  • Bell PRF, Briggs JD, Calman KC, Paton AM, Wood RFM, MacPherson SG (1971) Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone. Lancet 1: 876–880

    PubMed  CAS  Google Scholar 

  • Bemat JL, Sadowsky CH, Vincent FM, Nordgren RE, Margolis G (1976) Sclerosing spinal pachymeningitis. J Neurol Neurosurg Psychiatry 39: 1124–1128

    Google Scholar 

  • Bindoff L (1988) Methylprednisolone in multiple sclerosis: a comparative dose study. J Neurol Neurosurg Psychiatry 51: 1108–1109

    PubMed  CAS  Google Scholar 

  • Blomberg LH (1965) Comments on treatment of multiple sclerosis with ACTH. Acta Neurol Scand 41 (suppl 13): 485–486

    Google Scholar 

  • Boines GJ (1961) Remissions in multiple sclerosis. Delaware Med J 33: 230–235

    Google Scholar 

  • Boines GJ (1963) Predictable remissions in multiple sclerosis. Delaware Med J 35: 200–202

    PubMed  CAS  Google Scholar 

  • Bockman RS, Weinerman SA (1990) Steroid-induced osteoporosis. Orthop Clin North Am 21: 97–107

    PubMed  CAS  Google Scholar 

  • Boudin G, Barbizet J, Guihard J, Clop H (1953) Intraspinal hydrocortisone. Clinical applications, particularly in the treatment of tuberculous meningitis. Presse Medicale 63: 1072

    Google Scholar 

  • Brooks BR, Jubelt B, Cohen S, O’Donnelly P, Johnson RT, McKhann G (1979) Cerebrospinal fluid (CSF) myelin basic protein (MBP) in multiple sclerosis (MS): effect of prolonged high single-dose alternate-day prednisone therapy. Neurology 29: 548

    Google Scholar 

  • Buckley C, Kennard C, Swash M (1982) Treatment of acute exacerbations of multiple sclerosis with intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 45: 179–180

    PubMed  CAS  Google Scholar 

  • Butler WT (1975) Corticosteroids and immunoglobulin synthesis. Transplant Proc 7: 49–53

    PubMed  CAS  Google Scholar 

  • Carta F, Canu C, Datti R, Guiducci G, Pisani R, Silvestro C (1987) Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo-Medrol. Zentralbl Neurochir 48: 256–261

    PubMed  CAS  Google Scholar 

  • Cathcart ES, Idelson BA, Scheinberg MA, Counser WG (1976) Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet 1: 163–166

    PubMed  CAS  Google Scholar 

  • Cendrowski WS (1975) Pilot-study on large-dose alternate-day steroid therapy in multiple sclerosis. Schweiz Arch Neurol Psychiatr 117: 197–203

    CAS  Google Scholar 

  • Cendrowski W, Kuran W (1972) Results of combined administration of anabolic steroids in patients with multiple sclerosis. Neurol Neurochir Pol 6: 573–576

    PubMed  CAS  Google Scholar 

  • Citterio A, Bergamaschi R, Vercesi S, Cosi V (1987) High-dose methylprednisolone infusion in multiple sclerosis. Riv Neurol 57: 105–106

    Google Scholar 

  • Clamen HN (1972) Corticosteroids and lymphoid cells. N Engl J Med 287: 388–397

    Google Scholar 

  • Compston DA, Milligan NM, Hughes PJ et al. (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 2. Laboratory results. J Neurol Neurosurg Psychiatry 50: 517–522

    PubMed  CAS  Google Scholar 

  • Cupps TR, Fauci AS (1982) Corticosteroid-mediated immunoregulation in man. Immunol Rev 65: 133–155

    PubMed  CAS  Google Scholar 

  • Davis FA, Stefoski D (1988) Is steroid therapy in multiple sclerosis superior to corticotropin therapy? Arch Neurol 45: 1180

    PubMed  CAS  Google Scholar 

  • Di Munno O, Beghe F, Favini P et al. (1989) Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hyroxyvitamin D and calcium. Clin Rheumatol 8: 202–207

    PubMed  Google Scholar 

  • DiRosa M, Calignano A, Carnuccio R, Lalenti A, Sautebin L (1985) Multiple control of inflammation by glucocorticoids. Agents Actions 17: 284–289

    CAS  Google Scholar 

  • Dowling PC, Bosch VV, Cook SD (1980) Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology 30: 33–36

    PubMed  CAS  Google Scholar 

  • Durelli L, Cocito D, Riccio A et al. (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36: 238–243

    PubMed  CAS  Google Scholar 

  • Ellison GW (1990) Chronic progressive multiple sclerosis: steroids and immunosuppressive drugs In: Cook SD (ed) Handbook of multiple sclerosis. Marcel Dekker Inc, New York, pp 371–402

    Google Scholar 

  • Ellison GW, Myers LW, Mickey MR et al. (1989a) Clinical experience with azathioprine: the pros. Neurology 38 (suppl 2): 20–23

    Google Scholar 

  • Ellison GW, Myers LW, Mickey MR (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39: 1018–1026

    PubMed  CAS  Google Scholar 

  • Fadul CE, Lemann W, Thaler HT, Poser JB (1988) Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease. Neurology 38: 348–352

    PubMed  CAS  Google Scholar 

  • Fan PT, Yu DTY, Clements PJ, Eisman J, Bluestone R (1978) Effect of corticosteroids on the human immune response: comparison of one and three daily 1 gm intravenous pulses of methylprednisolone. J Lab Clin Med 91: 625–634

    PubMed  CAS  Google Scholar 

  • Fog T (1965) The long-term treatment of multiple sclerosis with corticoids. Acta Neurol Scand Suppl 13: 473–484

    PubMed  Google Scholar 

  • Funder JW, Sheppard K (1987) Adrenocortical steroids and the brain. Annu Rev Physiol 49: 397–411

    PubMed  CAS  Google Scholar 

  • Glaser GH, Merritt HH (1952) Effects of corticotropin ( ACTH) and cortisone on disorders of the nervous system. JAMA 148: 898–904

    CAS  Google Scholar 

  • Glaser GH, Randt CT, Hoefer PFA, Merritt HH, Traeger CH (1950) The influence of adrenocorticotropic hormone ( ACTH) on central nervous system and neuromuscular functions. Trans Am Neurol Assoc 75: 98–104

    CAS  Google Scholar 

  • Goas JY, Marion JL, Missoum A (1983) High dose intravenous methylprednisolone in acute exacerbations of multiple sclerosis. J Neurol Neurosurg Psychiatry 46: 99

    PubMed  CAS  Google Scholar 

  • Goldstein NP, McKenzie BF, McGuckin WF (1962) Changes in cerebrospinal fluid of patients with multiple sclerosis: A preliminary report. Proc Mayo Clin 37: 657

    CAS  Google Scholar 

  • Goldstein NP, McKenzie BF, McGuckin WF, Mattox VR (1970) Experimental intrathecal administration of methylprednisolone acetate in multiple sclerosis. Tran Am Neurol Assoc 95: 243–244

    CAS  Google Scholar 

  • Haynes RC Jr (1990) Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs: inhibitors of the synthesis and actions of adrenocortical hormones. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds), Goodman and Gilman’s pharmacological basis of therapeutics, 8th edn. Pergamon Press, New York, pp 1440–1462

    Google Scholar 

  • Haynes BF, Fauci AS (1978) The differential effect of in vitro hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. J Clin Invest 61: 703–707

    PubMed  CAS  Google Scholar 

  • Herndon RM (1987) The effect of drugs on oligodendrocyte proliferation and myelin regeneration. Prog Brain Res. 71: 485–491

    PubMed  CAS  Google Scholar 

  • Johnson HM, Smith EM, Torres BA et al. (1982) Regulation of the in vitro antibody response by neuroendocrine hormones. Proc Nati Acad Sci US 79: 4171–4174

    CAS  Google Scholar 

  • Jonsson B, von Reis G, Sahigren E (1951) Experience of ACTH and cortisone treatment in some organic neurological cases. Acta Psychiatr Neurol Scand (Suppl 74 ) 60–63

    CAS  Google Scholar 

  • Kalurian KC, Hahn BH, Bassett L (1989) Magnetic resonance imaging identifies early femoral head ischemic necrosis in patients receiving glucocorticoid therapy. J Rheumatol 16: 959–963

    Google Scholar 

  • Kamen GF, Erdman GL (1953) Subdural administration of hydrocortisone in multiple sclerosis: effect of ACTH. J Am Geriatr Soc 1: 794–804

    PubMed  CAS  Google Scholar 

  • Kane CA (1964) Skeletal muscle spasms and spasticity: clinical considerations. Clin Pharmacol Ther 5: 852–858

    Google Scholar 

  • Ketelaer CJ, Delmotte P (1972) Results of adrenal and pituitary stimulation tests in patients with multiple sclerosis. Acta Neurol Scand 48: 467–478

    PubMed  CAS  Google Scholar 

  • Kibler RF (1965) Large dose corticosteroid therapy of experimental and human demyelinating diseases. Ann NY Acad Sci 122: 469–479

    PubMed  CAS  Google Scholar 

  • Kurki P (1984) The effects of “pulse” corticosteroid therapy on the immune system. Scand J Rheumatol 154 (Suppl): 13–15

    Google Scholar 

  • Kurtzke JF (1965) Further notes on disability evaluation in multiple sclerosis with scale modifications. Neurology 15: 654–661

    PubMed  CAS  Google Scholar 

  • Lance JW (1969) Intrathecal “Depo-Medrol” for spasticity. Med J Aust 2: 1030

    Google Scholar 

  • Liebling MR, McLaughlin K, Boonsue S, Kasdin J, Barnett EW (1982) Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 9: 543–548

    PubMed  CAS  Google Scholar 

  • Lyons PR, Newman PK, Saunders M (1988) Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 51: 285–287

    PubMed  CAS  Google Scholar 

  • Maida E, Summer K (1979) Serum cortisol levels of multiple sclerosis patients during ACTH treatment. J Neurol 220: 143–149

    PubMed  CAS  Google Scholar 

  • Massaro AR (1978) Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids. Neurology 219: 221–226

    CAS  Google Scholar 

  • Mazzarello P, Poloni M, Piccolo G, Cosi V, Pinelli P (1983) Intrathecal methylprednisolone acetate in multiple sclerosis treatment. Acta Neurol Belg 83: 190–196

    PubMed  CAS  Google Scholar 

  • McDougal BA, Whittier FC, Cross DE (1976) Sudden death after bolus steroid therapy for acute rejection. Transplant Proc 8: 493

    PubMed  CAS  Google Scholar 

  • McEwen BS, DeKloet ER, Rostene W (1986) Adrenal steroid receptors and actions in the nervous system. Physiol Rev 66: 1121–1188

    PubMed  CAS  Google Scholar 

  • Merritt HH, Glaser GH, Herrmann C (1954) Study of short-and long-term effects of adrenal steroids on clinical patterns of multiple sclerosis. Ann NY Acad Sci 58: 625–632

    Google Scholar 

  • Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC (1983) Association of adrenocortico-steroid theapy and peptic-ulcer disease. N Engl J Med 309: 21–24

    PubMed  CAS  Google Scholar 

  • Milanese C, LaMantia L, Salmaggi A et al. (1989) Double-blind randomized trial of ACTH versus dexamethasone verus methylprednisolone in multiple sclerosis bouts. Eur Neurol 29: 10–14

    PubMed  CAS  Google Scholar 

  • Millar JHD, Vas CJ, Noronha MJ, Liversedge LA, Rawson MD (1967) Long-term treatment of multiple sclerosis with corticotrophin. Lancet 2: 429–431

    PubMed  CAS  Google Scholar 

  • Millar JHD, Rahman R, Vas CJ, Noronha MJ, Liversedge LA, Swinburn WR (1970) Effect of withdrawal of corticotrophin in patients on long-term treatment for multiple sclerosis. Lancet 1: 700–702

    PubMed  CAS  Google Scholar 

  • Miller H, Newell DJ, Ridley A (1961a) Multiple sclerosis trials of maintenance treatment with prednisolone and soluble aspirin. Lancet 1: 127–129

    PubMed  CAS  Google Scholar 

  • Miller H, Newell DJ, Ridley A (1961b) Multiple sclerosis. Treatment of acute exacerbations with corticotrophin ( ACTH ). Lancet 2: 1120–1122

    PubMed  CAS  Google Scholar 

  • Milligan NM, Necombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50: 511–516

    PubMed  CAS  Google Scholar 

  • Milligan NM, Newcombe R, Compston DAS (1988) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 51: 597–598

    Google Scholar 

  • Minden SL, Orav J, Schildkraut JJ (1988) Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology 38: 1631–1634

    PubMed  CAS  Google Scholar 

  • Myers LW (1990) Management of multiple sclerosis. Autoimmunity Forum Neurology 2: 3–5

    Google Scholar 

  • Myers LW, Ellison GW (1990) The peculiar difficulties of therapeutic trials for multiple sclerosis. Clin Neuropharmacol 8: 119–141

    CAS  Google Scholar 

  • Naess A, Nyland H (1981) Effect of ACTH treatment on CSF and blood lymphocyte subpopulations in patients with multiple sclerosis. Acta Neurol Scand 63: 57–66

    PubMed  CAS  Google Scholar 

  • Narang PK, Wilder R, Chatterji DC, Yeager RL, Gallelli JF (1983) Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following high-dose pulse administration. Biopharm Drug Dispos 4: 233–248

    PubMed  CAS  Google Scholar 

  • Nelson D (1976) Arachnoiditis from intrathecally given corticosteroids in the treatment of multiple sclerosis. Arch Neurol 33: 373

    PubMed  CAS  Google Scholar 

  • Nelson DA, Yates TS Jr, Thomas RB Jr (1973) Complications from intrathecal steroid therapy in patients with multiple sclerosis. Acta Neurol Scand 49: 166–188

    Google Scholar 

  • Newman PK, Saunders M, Tilley PJB (1982) Methylprednisolone therapy in multiple sclerosis. J Neurol Neurosurg Psychiatry 45: 941–942

    PubMed  CAS  Google Scholar 

  • Poser S (1989) Corticotropin is superior to corticosteroids in the treatment of MS. Arch Neurol 46: 946

    PubMed  CAS  Google Scholar 

  • Prysee-Phillips WEM, Chandra RK, Rose B (1984) Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis. Neurology 34: 1119–1121

    Google Scholar 

  • Ringer WA (1968) The treatment of multiple sclerosis with intrathecally administered methylprednisolone acetate. J Indiana St Med Assoc 61: 1213–1215

    CAS  Google Scholar 

  • Rinne JK, Sonninen V, Tuovinen T (1968) Corticotrophin treatment in multiple sclerosis. Acta Neurol Scand 44: 207–218

    PubMed  CAS  Google Scholar 

  • Rivera VM (1981) Intraspinal steroid therapy. Neurology 31: 1060

    PubMed  CAS  Google Scholar 

  • Rivera VM (1989) Safety of intrathecal steroids in multiple sclerosis. Arch Neurol 46: 718

    PubMed  CAS  Google Scholar 

  • Rohrbach E, Kappos L, Stadt D et al. (1988) Intrathecal versus oral corticosteroid therapy of spinal symptoms in multiple sclerosis: A double-blind controlled trial. Neurology 38 (suppl 1): 256

    Google Scholar 

  • Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW (1970) Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo. Final report. Neurology 20: 1–59

    Google Scholar 

  • Snyder BD, Lakatua DJ; Doe RP (1981) ACTH-induced cortisol production in multiple sclerosis. Ann Neurol 10: 388–389

    PubMed  CAS  Google Scholar 

  • Spiro HM (1983) Is the steroid ulcer a myth? (editorial). N Engl J Med 309: 45–48

    PubMed  CAS  Google Scholar 

  • Stefoski D, Davis FA, Schauf CL (1985) Acute improvement in exacerbating multiple sclerosis produced by intravenous administration of mannitol. Ann Neurol 18: 443–450

    PubMed  CAS  Google Scholar 

  • Thompson AJ, Kennard C, Swash M et al. (1989) Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapses in MS. Neurology 39: 969–971

    PubMed  CAS  Google Scholar 

  • Torbergsen T (1972) The influence of ACTH-treatment on spinal fluid gamma globulins in multiple sclerosis. Acta Neurol Scand Suppl 48: 41

    Google Scholar 

  • Tourtellotte WW, Haerer AF (1965) Use of oral corticosteroids in the treatment of multiple sclerosis. Arch Neurol 12: 536–545

    PubMed  CAS  Google Scholar 

  • Tourtellotte WW, Potvin AR, Mendez M et al. (1980) Failure of intravenous and intrathecal cytarabine to modify central nervous system IgG synthesis in multiple sclerosis. Ann Neurol 8: 402–408

    PubMed  CAS  Google Scholar 

  • Tourtellotte WW, Staugaitis SM, Walsh MJ et al. (1985) The basis of intra-blood-brain-barrier IgG synthesis. Ann Neurol 17: 21–27

    PubMed  CAS  Google Scholar 

  • Troiano R, Hafstein M, Ruderman M, Dowling P, Cook S (1984) Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Ann Neurol 15: 257–263

    PubMed  CAS  Google Scholar 

  • Troiano R, Cook SD, Dowling PC (1987) Steroid therapy in multiple sclerosis: point of view. Arch Neurol 44: 803–807

    PubMed  CAS  Google Scholar 

  • Troiano R, Cook SD, Dowling PC (1990) Corticosteroid therapy in acute multiple sclerosis. In: Cook SD (ed) Handbook of multiple sclerosis. Marcel Dekker Inc, New York, pp 351–369

    Google Scholar 

  • Trotter JL, Garvey WF (1980) Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology 30: 702–708

    PubMed  CAS  Google Scholar 

  • Van Buskirk C, Poffenbarger AL, Capriles LF, Idea BV (1964) Treatment of multiple sclerosis with intrathecal steroids. Neurology 14: 595–597

    Google Scholar 

  • Warren KG, Catz T, Jeffrey VM, Carroll DJ (1986) Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci 13: 25–30

    PubMed  CAS  Google Scholar 

  • Yahr MD, Kabat EA (1957) Cerebrospinal fluid and serum gamma globulin levels in multiple sclerosis: changes induced by large doses of prednisone. Trans Am Neurol Assoc 82: 115–119

    PubMed  Google Scholar 

  • Zizic TM, Marcoux C (1985) Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 79: 596–604

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Lawrence W. Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195-5244, Cleveland, OH, USA

    Richard A. Rudick MD  & Donald E. Goodkin MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag London Limited

About this chapter

Cite this chapter

Myers, L.W. (1992). Treatment of Multiple Sclerosis with ACTH and Corticosteroids. In: Rudick, R.A., Goodkin, D.E. (eds) Treatment of Multiple Sclerosis. Clinical Medicine and the Nervous System. Springer, London. https://doi.org/10.1007/978-1-4471-3184-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3184-7_6

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-3186-1

  • Online ISBN: 978-1-4471-3184-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation